BenevolentAI S.A. (2XA.F)
| Previous close | 0.6300 |
| Open | 0.5960 |
| Bid | 0.6200 x N/A |
| Ask | 0.6800 x N/A |
| Day's range | 0.5960 - 0.6200 |
| 52-week range | 0.4460 - 2.0400 |
| Volume | |
| Avg. volume | 331 |
| Market cap | 80.827M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -55.7400 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
BenevolentAI: Publication of the Revised Agenda for the 2024 AGM
LONDON, April 17, 2024--Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the publication of the Revised Agenda for its Annual General Meeting set to be held on 2 May 2024 at 14:00 CEST at 2, place Winston Churchill, L-1340 Luxembourg (the "2024 AGM") (the "Revised Agenda").
- Business Wire
Proposed Changes to BenevolentAI’s Board Composition
LONDON, April 15, 2024--Regulatory News: BenevolentAI (or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that following extensive discussions with Mr. Kenneth Mulvany, founder and former Chairman of BenevolentAI Limited and a Non-Executive Director of BenevolentAI, several resolutions will be put forward at the Company’s upcoming Annual General Meeting ("AGM") relating to the future membership of the board of the
- Business Wire
BenevolentAI Announces Positive Topline Safety and Pharmacokinetic Data from the Phase Ia Clinical Study of BEN-8744 in Healthy Volunteers
LONDON, March 25, 2024--Regulatory News: BenevolentAI ("BenevolentAI" or the "Company") (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces positive safety data from its Phase Ia, first-in-human, clinical study of BEN-8744 in healthy volunteers.
